According to Zacks, “Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company’s principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden City, New York. “
Separately, ValuEngine raised shares of BeyondAirInc . from a hold rating to a buy rating in a research note on Tuesday, October 15th.
XAIR stock opened at $4.17 on Friday. The stock’s 50-day moving average price is $4.67. BeyondAirInc . has a 52-week low of $3.11 and a 52-week high of $6.25. The stock has a market cap of $48.13 million, a price-to-earnings ratio of -4.96 and a beta of -0.27.
BeyondAirInc . (NASDAQ:XAIR) last posted its earnings results on Wednesday, August 14th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.20). The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $1.25 million. On average, equities research analysts expect that BeyondAirInc . will post -1.14 earnings per share for the current fiscal year.
About BeyondAirInc .
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
Further Reading: Should I follow buy, hold and sell recommendations?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.